Cargando…
Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis
A 43-year-old Japanese woman with rheumatoid arthritis treated by infliximab and methotrexate for 11 years was admitted for proteinuria and purpura. A kidney biopsy revealed endothelial damage-dominant nephritis with IgA deposition. Infliximab and methotrexate were discontinued, and tocilizumab was...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876708/ https://www.ncbi.nlm.nih.gov/pubmed/35650123 http://dx.doi.org/10.2169/internalmedicine.9059-21 |
_version_ | 1784878222746320896 |
---|---|
author | Fukuda, Makoto Sawa, Naoki Ikuma, Daisuke Oba, Yuki Mizuno, Hiroki Yamanouchi, Masayuki Sekine, Akinari Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Kono, Kei Kinowaki, Keiichi Ohashi, Kenichi Tamaki, Hiromichi Miyazono, Motoaki Ubara, Yoshifumi |
author_facet | Fukuda, Makoto Sawa, Naoki Ikuma, Daisuke Oba, Yuki Mizuno, Hiroki Yamanouchi, Masayuki Sekine, Akinari Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Kono, Kei Kinowaki, Keiichi Ohashi, Kenichi Tamaki, Hiromichi Miyazono, Motoaki Ubara, Yoshifumi |
author_sort | Fukuda, Makoto |
collection | PubMed |
description | A 43-year-old Japanese woman with rheumatoid arthritis treated by infliximab and methotrexate for 11 years was admitted for proteinuria and purpura. A kidney biopsy revealed endothelial damage-dominant nephritis with IgA deposition. Infliximab and methotrexate were discontinued, and tocilizumab was started; however, proteinuria persisted. Therefore, tocilizumab was discontinued, and oral prednisolone and methylprednisolone pulse therapy were administered. After 6 months, urinary protein was less than 0.1 g/day, and purpura subsided. To our knowledge, this is the first case of endothelial damage-dominant nephritis related to IgA vasculitis involving the skin and kidney after long-term use of infliximab and methotrexate. |
format | Online Article Text |
id | pubmed-9876708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-98767082023-02-02 Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis Fukuda, Makoto Sawa, Naoki Ikuma, Daisuke Oba, Yuki Mizuno, Hiroki Yamanouchi, Masayuki Sekine, Akinari Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Kono, Kei Kinowaki, Keiichi Ohashi, Kenichi Tamaki, Hiromichi Miyazono, Motoaki Ubara, Yoshifumi Intern Med Case Report A 43-year-old Japanese woman with rheumatoid arthritis treated by infliximab and methotrexate for 11 years was admitted for proteinuria and purpura. A kidney biopsy revealed endothelial damage-dominant nephritis with IgA deposition. Infliximab and methotrexate were discontinued, and tocilizumab was started; however, proteinuria persisted. Therefore, tocilizumab was discontinued, and oral prednisolone and methylprednisolone pulse therapy were administered. After 6 months, urinary protein was less than 0.1 g/day, and purpura subsided. To our knowledge, this is the first case of endothelial damage-dominant nephritis related to IgA vasculitis involving the skin and kidney after long-term use of infliximab and methotrexate. The Japanese Society of Internal Medicine 2022-05-31 2023-01-01 /pmc/articles/PMC9876708/ /pubmed/35650123 http://dx.doi.org/10.2169/internalmedicine.9059-21 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Fukuda, Makoto Sawa, Naoki Ikuma, Daisuke Oba, Yuki Mizuno, Hiroki Yamanouchi, Masayuki Sekine, Akinari Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Kono, Kei Kinowaki, Keiichi Ohashi, Kenichi Tamaki, Hiromichi Miyazono, Motoaki Ubara, Yoshifumi Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title | Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title_full | Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title_fullStr | Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title_full_unstemmed | Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title_short | Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
title_sort | endothelial damage-dominant nephritis related to iga vasculitis after 11 years' use of infliximab for rheumatoid arthritis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876708/ https://www.ncbi.nlm.nih.gov/pubmed/35650123 http://dx.doi.org/10.2169/internalmedicine.9059-21 |
work_keys_str_mv | AT fukudamakoto endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT sawanaoki endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT ikumadaisuke endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT obayuki endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT mizunohiroki endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT yamanouchimasayuki endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT sekineakinari endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT hasegawaeiko endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT suwabetatsuya endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT hoshinojunichi endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT konokei endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT kinowakikeiichi endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT ohashikenichi endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT tamakihiromichi endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT miyazonomotoaki endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis AT ubarayoshifumi endothelialdamagedominantnephritisrelatedtoigavasculitisafter11yearsuseofinfliximabforrheumatoidarthritis |